Qing Pan

Dr. Qing Pan

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
QPQing Pan
Qing Pan
AAAdla Angelina
Adla Angelina
MMMichael Marrone
Michael Marrone
WSWalter J Stark
Walter J Stark
EAEsen K Akpek
Esen K Akpek

27 August 2013
Verified
Reference Entry
Closed access
PDF file
QPQing Pan
Qing Pan
AAAdla Angelina
Adla Angelina
AZAndrea Zambrano
Andrea Zambrano
MMMichael Marrone
Michael Marrone
WSWalter J Stark
Walter J Stark
EAEsen K Akpek
Esen K Akpek

2 September 2011 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
QPQing Pan
Qing Pan
XLXiuyi Li
Xiuyi Li
YGYangshun Gu
Yangshun Gu

11 November 2016 in Eye
Verified
Journal Article
Closed access
QPQing Pan
Qing Pan
HJH D Jampel
H D Jampel
PRP Ramulu
P Ramulu
GSG F Schwartz
G F Schwartz
FCF Cotter
F Cotter
WSW J Stark
W J Stark

1 August 2021 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JBJiaxin Bian
Jiaxin Bian
HCHongyu Chen
Hongyu Chen
JSJunhui Sun
Junhui Sun
YCYuqing Cao
Yuqing Cao
JAJianhong An
Jianhong An
MQMing Qi
Ming Qi
Purpose: The aim of study was to establish Rdh12-associated inherited retinal disease (Rdh12-IRD) mouse model and to identify the best timepoint for gene therapy. Methods: We induced retinal degeneration in Rdh12−/− mice using a bright light. We clarified the establishment of Rdh12-IRD mouse model by analyzing the thickness of retinal layers and electroretinography (ERG). Rdh12-IRD mice received a subretinal injection of adeno-associated virus 2/8-packaged Rdh12 cDNA for treatment. We evaluated the visual function and retinal structure in the treated and untreated eyes to identify the best timepoint for gene therapy. Results: Rdh12-IRD mice showed significant differences in ERG amplitudes and photoreceptor survival compared to Rdh12+/+ mice. Preventive gene therapy not only maintained normal visual function but also prevented photoreceptor loss. Salvage gene therapy could not reverse the retinal degeneration phenotype of Rdh12-IRD mice, but it could slow down the loss of visual function. Conclusion: The light-induced retinal degeneration in our Rdh12−/− mice indicated that a defect in Rdh12 alone was sufficient to cause visual dysfunction and photoreceptor degeneration, which reproduced the phenotypes observed in RDH12-IRD patients. This model is suitable for gene therapy studies. Early treatment of the primary Rdh12 defect helps to delay the later onset of photoreceptor degeneration and maintains visual function in Rdh12-IRD mice.

27 June 2023 in Frontiers in Ophthalmology
Verified
Journal Article
Open access
PDF file
JXJianhua Xia
Jianhua Xia
LGLei Gu
Lei Gu
QPQing Pan
Qing Pan
The study of gene therapies has been of particular interest in recent decades due to their promising potential to slow or even rescue the degeneration of the retina in inherited retinal dystrophies (IRDs). Here, we review the current approaches to gene therapy trials on IRDs, including the selection of animal models, therapeutic window, vectors and dosages. Mice are typically the first choice of animal models and recombinant adeno-associated virus (rAAV) of serotype 8 is the most common vector for loss-of-function IRDs. Furthermore, the therapeutic window should be considered to ensure efficacy before retinal degeneration occurs if possible, and dosages must be tailored to each approach.